Diabetes mellitus, obesity, and hepatic steatosis

Seminars in Gastrointestinal Disease

Volumn 13, Issue 1, 2002, Pages 17-30

  Youssef, Wael ^a   McCullough, Arthur J ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIOXIDANT; BETAINE; BILE ACID; CYTOKINE; ETANERCEPT; GEMFIBROZIL; INFLIXIMAB; METFORMIN; PENTOXIFYLLINE; TROGLITAZONE; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE COURSE; FATTY LIVER; FEMALE; HEPATITIS; HISTOLOGY; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID PEROXIDATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS; SCREENING; SYMPTOM;

ALGORITHMS; CHRONIC DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE PROGRESSION; FATTY LIVER; HUMANS; OBESITY;

EID: 0036208020     PISSN: 10495118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (126)

1. Non-alcoholic steatohepatitis. Mayo clinic experiences with a hither to unnamed disease
2. Non-alcoholic steatohepatitis: A study of 49 patients
3. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years
4. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity
5. Non-alcoholic fatty liver disease: Assessment of variability in pathologic interpretations
6. Clinical features and natural history of non-alcoholic steatosis syndromes
7. Metabolic and nutritional considerations in nonalcoholic fatty liver
8. Association of nonalcoholic fatty liver disease with insulin resistance
9. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome
10. Nonalcoholic steatohepatitis: Association of insulin resistance
11. Liver pathology and the metabolic syndrome X in severe obesity
12. Nonalcoholic steatohepatitis: An expanded clinical entity
13. The natural history of nonalcoholic fatty liver: A follow-up study
14. Alcohol-like liver disease in non-alcoholics. A clinical and histologic comparison with alcohol-induced liver injury
15. Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis
16. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis
17. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis
18. Non-alcoholic steatohepatitis
19. Hepatic iron and nonalcoholic fatty liver disease
20. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease
21. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study
22. Fatty liver hepatitis (steatohepatitis and obesity; an autopsy study) with analysis of risk factors
23. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus
24. Diabetes and non-alcoholic fatty liver disease: A worrisome combination
25. Hepatic morphology in obesity
26. Fatty metamorphosis of the liver in morbid obesity
27. Liver histology abnormalities in the morbidly obese
28. Subcapsular steatonecrosis in response to peritoneal insulin delivery: A clue to the pathogenesis of steatonecrosis in obesity
29. Liver function in moderate obesity - Study in 534 moderately obese subjects among 4613 male company employees
30. Liver fibrosis in overweight patients
31. Steatohepatitis: A tale of two "hits"?
32. Hepatic steatosis innocent bystander or guilty party?
33. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen 1(I) gene expression in human liver fat-storing cells
34. Activation of hepatic stellate cells by TGF and collagen type I is mediated by oxidative stress through c-myb expression
35. Stimulation of collagen alpha 1 (I) gene expression is associated with lipid peroxidation in hepatocellular injury: A link to tissue fibrosis?
36. Body fat topography as an independent prediction of fatty liver
37. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin resistant black men with NIDDM
38. Prevalence of fatty liver in japanese children and relationship to obesity. An epidemiological ultrasonographic survey
39. Splanchnic insulin metabolism in obesity. Influence of body fat distribution
40. Insulin regulation of regional fee fatty acid metabolism
41. Calorie restriction reverses hepatic insulin resistance in aging rats by decreasing visceral fat
42. Surgical removal of visceral fat reverses hepatic insulin resistance
43. Clinicopathologic study of alcohol-like liver disease in nonalcoholics; non-alcoholic steatohepatitis and fibrosis
44. Liver and biliary ultrasonography in diabetic and non-diabetic obese women
45. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases
46. The bright liver syndrome: Prevalence and determinants of a "bright" liver echo pattern
47. Fatty infiltration f the liver: Analysis of prevalence, radiological and clinical features and influence on patient management
48. Prevalence of fatty liver in a general population of okinawa, japan
49. Prevalence of and risk factors for hepatic steatosis in northern Italy
50. Varying body mass index cut-off points to describe overweight prevalence among U.S. adults. NHANES III (1988-1994)
51. Obesity as a medical problem
52. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty
53. Fatty disease in morbid obesity
54. Prevalence of and risk factors for hepatic steatosis in northern Italy
55. Liver morphology in morbid obesity: A literature study
56. Liver in obesity
57. The world wide obesity epidemic
58. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: The third national health and nutrition examination survey, 1988-1994
59. Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the U.S.
60. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study
61. Emerging epidemic of type 2 diabetes in youth
62. Idiopathic steatohepatitis in childhood: A multicenter retrospective study
63. Nonalcoholic steatohepatitis in children
64. Obesity: A cause of steatohepatitis in children
65. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis
66. Fatty liver: A study of 270 patients with biopsy proven fatty liver and a review of the literature
67. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?
68. Non-alcoholic steatohepatitis: Clinicopathological comparison with alcohol hepatitis in ambulatory and hospitalized patient
69. Markers of chronic alcohol ingestion in patients with non-alcoholic steatohepatitis: An aid to diagnosis
70. Nonalcoholic steatohepatitis
71. Obesity and female gender increase breath ethanol concentration: Potential implications for the pathogenesis of non-alcoholic steatohepatitis
72. Diet, lifestyle and the risk of type 2 diabetes mellitus in women
73. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese
74. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver
75. Mitochondrial adaptation to obesity-related oxidant stress
76. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion
77. Alterations in liver ATP homeostasis in human non-alcoholic steatohepatitis. A pilot study
78. Etiopathogenesis of non-alcoholic steatohepatitis
79. Mitochondria in steatohepatitis
80. Acute and chronic steatosis lead to in vivo lipid peroxidation in mice
81. Hepatic cytochrome p450 2E1 is increased in patients with nonalcoholic steatohepatitis
82. Changes in microsomal activity in alcoholism and obesity
83. Characterization of pathogenic and prognostic factors of non-alcoholic steatohepatitis associated with obesity
84. Paroxysmal-oxidation and steatohepatitis
85. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis
86. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: Effect of the nutritional status
87. Comparison of serum concentrations of -tocopherol and -carotene in a cross-sectional sample of obese and non-obese children (NHANES III)
88. Reversal of obesity and diet-induced insulin resistance with salicylates or target disruption of IKKB
89. Nuclear migration of NF-KB correlates with TNF-mRNA accumulation
90. The lipid peroxidation and product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor beta 1 expression in the macrophage lineage: A link between oxidative injury and fibrosclerosis
91. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis
92. Animal models of steatosis
93. Oxidant stress in rat liver after lipopolysaccharide administration: Effect of inducible nitric-oxide synthesis inhibition
94. Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth
95. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxemia, and tumor necrosis factor in the pathogenesis of non-alcoholic steatohepatitis
96. The utility of radiographic assessments with CT, US and MRI in establishing the diagnosis of non-alcoholic fatty liver disease
97. Treatment of nonalcoholic fatty liver: Present and emerging therapies
98. Non-alcoholic steatohepatitis in obesity: A reversible condition
99. Effect of hepatitis morphology of treatment of obesity by fasting, reducing diets and small bowel bypass
100. Effect of weight reduction on hepatic abnormalities in overweight patients
101. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
102. Persistent hyperaminotranferasemia resolving after weight reduction in obese children
103. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population
104. Nonalcoholic steatohepatitis in children
105. Fasting in obesity: Another cause of liver injury with alcoholic hyaline?
106. Liver morphology and function tests in obesity and during total starvation
107. Hepatic effects of dietary weight loss in morbidly obese patients
108. Very low-calorie diets for the treatment of obesity
109. Non-alcoholic steatohepatitis: Association with obesity and insulin resistance and influence of weightloss
110. A pilot study of a thiazolidinedione, troglitazone in nonalcoholic steatohepatitis
111. Hepatic dysfunction associated with troglitazone
112. Hepatocellular injury in a patient receiving rosiglitazone
113. Metformin reverses fatty liver disease in obese, leptin-deficient mice
114. Metformin in non-alcoholic steatohepatitis
115. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
116. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: A pilot study
117. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis; Results of a pilot study
118. Treatment of nonalcoholic steatohepatitis with N-acetylcysteine
119. Role of tocopherols in the protection of biological systems against oxidative damage
120. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
121. Diagnostic significance of measurement of serum transforming growth factor (β1 (TGF-β1) level and effect of α-tocopherol in patients with nonalcoholic steatohepatitis
122. Mechanism of hepatoprotective action of bile acids in liver disease
123. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of anti-oxidants
124. Study of human isoursodeoxycholic acid metabolism
125. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis